Concepedia
Statistics
Publications
9
Citations
626
H-Index
Active since
1974
Affiliations
Novartis (United States)(Current)
Novartis (United Kingdom)
Tris Pharma (United States)
Syracuse University
Michael Dolker is an author at Novartis (United States) specializing in pharmacotherapy, medicine, and pharmacology.
Publications per year
1974–2010
Ventricular defibrillation using biphasic waveforms: The importance of phasic duration
Anthony Tang, Seitaro Yabe, J. Marcus Wharton et al. · Journal of the American College of Cardiology · 1989 · 178 citations
Medicine, Biomedical Engineering, Cardiology +16
QVA149 demonstrates superior bronchodilation compared with indacaterol or placebo in patients with chronic obstructive pulmonary disease
J.A. van Noord, Roland Buhl, Craig LaForce et al. · Thorax · 2010 · 115 citations · Full text
Medicine, Pharmacology, Pharmacotherapy +15
Orlistat improves blood pressure control in obese subjects with treated but inadequately controlled hypertension
George L. Bakris, David A. Calhoun, Brent M. Egan et al. · Journal of Hypertension · 2002 · 96 citations
Agriculture, Nutritional Sciences, Pharmacotherapy +17
Sustained 24-h efficacy of NVA237, a once-daily long-acting muscarinic antagonist, in COPD patients
C. Verkindre, Yoshinosuke Fukuchi, A. Flémale et al. · Respiratory Medicine · 2010 · 69 citations · Full text
Medicine, Pharmacology, Pharmacotherapy +12
Cardiovascular Safety of QVA149, a Combination of Indacaterol and NVA237, in COPD Patients
Boudewijn Van de Maele, Leonardo M. Fabbri, Rachael Horton et al. · COPD Journal of Chronic Obstructive Pulmonary Disease · 2010 · 61 citations · Full text
Pharmacy, Pharmacology, Pharmacotherapy +17
1–5 of 9